To the best of our knowledge, our results showing for the first time that AXL inhibitor is able to induce Mk differentiation suggesting the rebound proliferation when gilteritinib exhibits AXL inhibition disinhibiting high AXL levels in the AML patients (Figure 6). Here, AXL is linked to acute myeloid leukemia.